CN107793471B - Folate receptor alpha specific binding peptide 4 and application thereof - Google Patents
Folate receptor alpha specific binding peptide 4 and application thereof Download PDFInfo
- Publication number
- CN107793471B CN107793471B CN201710649314.8A CN201710649314A CN107793471B CN 107793471 B CN107793471 B CN 107793471B CN 201710649314 A CN201710649314 A CN 201710649314A CN 107793471 B CN107793471 B CN 107793471B
- Authority
- CN
- China
- Prior art keywords
- phage
- folate receptor
- receptor alpha
- cell
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000010451 Folate receptor alpha Human genes 0.000 title claims abstract description 15
- 108050001931 Folate receptor alpha Proteins 0.000 title claims abstract description 15
- 230000009870 specific binding Effects 0.000 title description 5
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 title description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 15
- 229920001184 polypeptide Polymers 0.000 claims abstract description 12
- 230000008685 targeting Effects 0.000 claims abstract description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 238000012216 screening Methods 0.000 abstract description 16
- 238000002823 phage display Methods 0.000 abstract description 10
- 206010028980 Neoplasm Diseases 0.000 abstract description 6
- 210000004881 tumor cell Anatomy 0.000 abstract description 4
- 238000002626 targeted therapy Methods 0.000 abstract description 2
- 238000009509 drug development Methods 0.000 abstract 1
- 239000002547 new drug Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 35
- 238000002965 ELISA Methods 0.000 description 23
- 230000027455 binding Effects 0.000 description 23
- 239000006228 supernatant Substances 0.000 description 23
- 239000000243 solution Substances 0.000 description 21
- 238000005406 washing Methods 0.000 description 19
- 239000007788 liquid Substances 0.000 description 15
- 238000012163 sequencing technique Methods 0.000 description 15
- 239000000872 buffer Substances 0.000 description 14
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 11
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 11
- 230000000903 blocking effect Effects 0.000 description 11
- 239000008055 phosphate buffer solution Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000006180 TBST buffer Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 5
- 238000010009 beating Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 239000002250 absorbent Substances 0.000 description 4
- 230000002745 absorbent Effects 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010067902 Peptide Library Proteins 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 102000006815 folate receptor Human genes 0.000 description 3
- 108020005243 folate receptor Proteins 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 238000007251 Prelog reaction Methods 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- OTQVMPMOOJXQFB-UHFFFAOYSA-N Cl.Cl.NCC(=O)O.NCC(=O)O Chemical compound Cl.Cl.NCC(=O)O.NCC(=O)O OTQVMPMOOJXQFB-UHFFFAOYSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101710157639 Minor capsid protein Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 101710136297 Protein VP2 Proteins 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010863 targeted diagnosis Methods 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to a short peptide specifically combined with folate receptor alpha and application thereof, belonging to the technical field of biology. The polypeptide sequence of the invention is YTNPYYSSHTRN. The polypeptide is obtained by screening from a phage display library, can be specifically combined with tumor cells expressing folate receptor alpha, provides a new targeting molecule for targeted therapy of tumors and tumor images, and has potential value of new drug development.
Description
The technical field is as follows:
the invention belongs to the technical field of biology, and relates to a short peptide specifically bound with folate receptor alpha and application thereof in tumor targeting.
Background art:
the phage display technology is to perform fusion expression on exogenous polypeptide or protein and a certain capsid protein of a phage, so that the exogenous protein can be displayed on the surface of a virus particle, and simultaneously, DNA encoding the exogenous protein is positioned in the virus particle. The random dodecapeptide phage display library is a combined library formed by fusing random dodecapeptide to M13 phage minor capsid protein (pIII). The displayed dodecapeptide is expressed at the N-terminus of pIII. This creates a direct bridge between a large number of random polypeptides and their DNA coding sequences, and then in vitro screening is performed with various target molecules (antibodies, enzymes, cell surface receptors, etc.) to obtain target molecule binding peptides. The in vitro selection procedure is simply the co-incubation of a phage library with a solid phase target molecule, washing to remove unbound phage, and then eluting to obtain phage capable of specifically binding to the target molecule. The eluted phage is then amplified for the next binding/amplification cycle to enrich for specifically binding phage. After 3-4 rounds of "panning", each specifically bound polypeptide sequence can be obtained by DNA sequencing.
Folate Receptors (FRs) are important transporters that bind and transport folate and its derivatives into cells, and exist in vivo primarily as three subtypes: FR α, β and γ. Folate receptor alpha (FR α) is a glycoprotein anchored to the surface of cell membranes by Glycosylated Phosphatidylinositol (GPI). The FR alpha in tissues such as ovarian cancer, lung cancer, liver cancer, breast cancer and the like is high in expression and limited in expression in normal tissues, so that the FR alpha is considered as an ovarian cancer marker or Tumor Associated Antigen (TAA) with great potential; the FR alpha has high specificity to ovarian cancer and can be used as a target for treating related tumors; some studies have also shown that FR α is of great value for the early diagnosis of ovarian cancer. Based on the above, if a short peptide sequence with higher affinity with the FR alpha can be obtained, a new idea is provided for targeted therapy and diagnosis of the tumor.
Disclosure of Invention
Object of the Invention
The invention aims to obtain a polypeptide capable of being specifically combined with a folate receptor alpha by utilizing a phage display technology. The polypeptide can be used for targeting tumor cells positive in folate receptor alpha expression.
Technical scheme
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
1) affinity screening of phage display peptide libraries: the folic acid receptor alpha recombinant protein is used as a target, and four rounds of biological screening are carried out by using a phage display dodecapeptide library. Detecting recovery rate and polyclonal ELISA by each screening to judge whether the screening is effective; detecting the binding capacity of each clone and the folate receptor alpha recombinant protein by monoclonal ELISA;
2) preparing phage positive monoclonal DNA and sequencing and identifying: selecting phage monoclone with high positive value according to the ELISA result, amplifying the phage monoclone, quickly purifying a sequencing module to generate a sufficiently pure template for sequencing, selecting-96 gIII sequencing primers to send to a company for sequencing, and analyzing a corresponding display peptide sequence of the positive phage;
3) cell ELISA detects binding of phage clones to native cell surface folate receptor alpha: selecting an FR alpha expression positive cell strain SKOV3, and detecting the combination of phage clone and cell strain by ELISA by taking an FR alpha expression negative cell strain HepG2 as a control;
4) the binding of the phage clones to the FR α expression positive cell line SKOV3 was further confirmed by flow cytometry.
Advantageous effects
The FR alpha binding peptide provided by the invention can be specifically bound with FR alpha recombinant protein, and meanwhile, through cell ELISA and flow cytometry experimental analysis, the screened phage display short peptide can be specifically bound with natural FR alpha on the surface of a cell, so that the FR alpha binding peptide has potential medical and pharmaceutical values.
Description of the drawings:
FIG. 1 polyclonal ELISA;
FIG. 2 is a graph showing the study of the binding ability of positive monoclonals to folate receptor alpha recombinant proteins. FIG. 2A. monoclonal phage ELISA screening positive clones (the circled clones are folate receptor alpha specific binding peptide 4 display clones); FIG. 2B further validation of binding of positive monoclonals to folate receptor alpha recombinant protein;
FIG. 3 shows that the positive monoclonal antibody screened by ELISA is combined with SKOV3, which is a FR alpha expression positive cell, and M13 and HepG2, which is a FR alpha expression negative cell, are used as controls;
FIG. 4. flow cytometry analysis of the specific binding of positive monoclonal antibodies to SKOV3, for the control group, only SKOV3 cells with anti-M13 antibody and FITC fluorescent antibody were added, as indicated by the dashed line in the figure.
The specific implementation mode is as follows:
while the following provides more particular embodiments for purposes of illustrating the invention more clearly, it will be understood by those skilled in the art that the present invention is not limited to the examples set forth below.
Example 1 affinity screening of phage display peptide libraries
Random dodecapeptide phage display libraries were purchased from NEB, 100. mu.l, with titers of 1.5 × 1013pfu/ml. Stored in 50% glycerol in TBS buffer (50mM Tris-HCl, 150mM NaCl [ pH7.5 ]]) Medium, reservoir capacity 2.7 × 109And (4) a transformant. Escherichia coil ER2738 is the host bacterium for the peptide library.
(1) Preparation work
The FR α recombinant protein was diluted with a coating buffer (carbonate buffer [ pH9.6]) to a final concentration of 50 μ g/ml, and the diluted solution was coated on an ELISA plate at 100 μ l per well, and the rotation was repeated until the surface was completely wetted. Incubate overnight at 4 ℃ in a wet box.
(2) Affinity screening
The next day, the coating solution was poured off the microplate and applied to TBST buffer (TBS + 0.1% by volume [ v/v ]]Tween-20) plates were washed, buffer was decanted, and residual liquid was removed by patting on clean absorbent paper. Then 200. mu.l of blocking solution (0.1M NaHCO) was added to each well3,5mg/ml BSA,0.02%NaN3[PH8.6]) Putting the mixture into a wet box, incubating the mixture at 4 ℃ overnight or incubating the mixture at 37 ℃ for at least 1 hour, discarding the blocking solution, filling TBST buffer solution into each hole, washing the plate for 6 times, washing the plate for 5 minutes each time, putting the plate on a decoloration shaking bed for carrying out washing, then pouring the buffer solution, beating and throwing the buffer solution on clean absorbent paper to remove residual liquid, quickly carrying out the experimental step to avoid drying the hole plate, diluting the original library by using the TBST buffer solution, taking 100 mu l of the diluted library solution, adding the library solution into the micropore of the ELISA plate which is coated with FR α recombinant protein in advance, wherein the quantity of the added phage is about 5 × 1012. Incubate overnight at 4 ℃ or 2 hours at 37 ℃ in a wet box, discard the well contents, flap the plate upside down to remove residual solution, and wash the plate 10 times with TBST buffer, as before (wash away unbound phage). After the final wash, the well is patted clean, and 100. mu.l of a nonspecific buffer such as 0.2M Glycine-Glycine hydrochloride-HCl buffer [ pH2.2 ] is added to the wells of the microplate]To elute the bound phage, gently shaking on a decolorizing shaker for 10 minutes at room temperature to allow for sufficient elution, followed by 15. mu.l of 1M Tris-HCl [ pH9.1 ]]The eluate was neutralized and transferred to a clean EP tube. Taking 5 μ l of eluent by conventional M13 method for determining eluate titer, adding the rest eluent into 20ml of ER2738 strain in early log phase for first round phage eluate amplification, shake culturing at 37 deg.C and 220rpm for 4.5 hr, transferring the amplified product into a clean centrifuge tube, centrifuging at 4 deg.C and 10,000rpm for 10 min, taking about 80% of phage supernatant, transferring into another clean centrifuge tube, adding 1/6 volume of PEG/NaCl (20% [ w/v ])]PEG-800,2.5M NaCl)Phage precipitation was performed by standing at 4 ℃ for at least 1 hour or overnight. Centrifugation was carried out at 10,000rpm for 10 minutes at 4 ℃ and the residual supernatant was discarded by a micropipette, and the supernatant was thoroughly aspirated by brief centrifugation. The pellet was resuspended in 200. mu.l TBS buffer, centrifuged again and the supernatant was transferred to a clean centrifuge tube, the amplified eluate. Mu.l of the eluate was taken for determination of phage titer, and the remainder was used for the second round of affinity screening. The steps are repeated for four rounds of screening. Round-by-round screening increased the number of washes of TBST in the wash step.
(3) Determination of phage titer
Inoculating ER2738 strain in 10ml LB culture medium, shake culturing at 37 deg.C to middle logarithmic phase (OD)600Around 0.5). During the process, the upper layer agar is heated and dissolved in a microwave oven, and is subpackaged into 5ml sterilized EP tubes, wherein each tube is 3ml, the number of the tubes is determined according to the dilution gradient of the phage, and only one tube is needed for each dilution gradient. The subpackaged EP pipes are placed in a water bath kettle at 45 ℃ for standby; meanwhile, LB/IPTG/Xgal culture plates were prepared and placed in a 37 ℃ incubator for use. The collected phage supernatant was diluted with LB medium in a 10-fold gradient (general dilution range of amplified phage: 10)8~1011) After dilution, 10 mul of diluted matters in various gradients are immediately added into a plurality of 1.5ml sterilized EP tubes, and each tube is 200 mul, the diluted matters in various gradients are immediately added into the EP tubes containing bacterial liquid, after shaking and mixing, incubation is carried out for 5 minutes at 37 ℃, then upper agar placed at 45 ℃ is taken out, the contents in the tubes are immediately and completely transferred into upper agar, the tubes are quickly inverted and mixed, poured onto pre-warmed LB/IPTG/Xgal culture plates, the plates are gently shaken to evenly distribute the upper agar, after cooling and solidification for a period of time, inverted culture is carried out at 37 ℃ for overnight, plates with the total number of the plaques being about 100 are selected, the number of the plaques growing on the plates is counted, the titer (pfu) of the phage is calculated, the quantity of the phage screened in each round (Input titer Input), the quantity of the eluted phage (Output titer Output), the Output ratio of each round is calculated, the enrichment degree reflecting the specificity (enrichment degree) of the Recovery, and the enrichment degree of the recombined proteins screened by four rounds of specificity α binding affinity binding with the FR, and the recombined proteins are subjected to be subjected to high affinity screening, and the FR is calculatedThe force phages were effectively enriched (see table 1).
TABLE 1 Titers, Titers exported and recoveries from each round
Example 2 phage polyclonal ELISA identification
FR α recombinant protein was treated with carbonate buffer [ pH9.6]Diluted to a final concentration of 10. mu.g/ml, coated with 100. mu.l per well, overnight at 4 ℃. Discarding the target molecule solution every other day, beating and throwing on clean absorbent paper to remove residual liquid, drying, washing once with TBS buffer solution, adding 200 μ l of blocking solution into each hole, and standing at 37 ℃ for 1-2 hours. The blocking solution was spun off, washed 3 times with TBS buffer 5 minutes each time, patted vigorously on clean absorbent paper, and the wash was spun off. After washing, 100. mu.l of diluted eluate (i.e., phage supernatant) from each round of screening amplification was added to each well, incubated at 37 ℃ for 2 hours, the well liquid was discarded, and washed with TBST buffer and TBS buffer for 5 minutes each time, after removing the washing liquid by beating, the HRP-labeled mouse anti-M13 antibody was added as a secondary antibody (diluted to working concentration with blocking solution), incubated at 37 ℃ for 2 hours, the well liquid was discarded, and the washing operation was the same as the above. Adding 100 mul TMB substrate solution into each hole for developing, incubating for 10 minutes at room temperature in a dark place, and changing the liquid in the holes from colorless to blue; add 50. mu.l of 1M H per well2SO4Stopping the color reaction in a stopping solution, and detecting OD on a microplate reader450The value is obtained.
The results showed that the affinity of the eluate for binding to the FR α recombinant protein increased gradually as the number of screening rounds increased, but decreased somewhat at the fourth round (see fig. 1).
Example 3 ELISA and sequencing identification of phage monoclonals
(1) ELISA (enzyme-Linked immuno sorbent assay) for detecting binding capacity of monoclonal phage display short peptide to target molecule
Obtaining the phage to be detected: the strain ER2738 was inoculated in advance, cultured at 37 ℃ to the pre-log stage, and the pre-log culture was transferred to a 2ml deep well plate at 600. mu.l per well. Plates for titer detection (plates with a total of about 100 plaques and less) were selected from four rounds of screening, and a plurality of blue plaques were randomly picked with a tip into a deep well plate and incubated with a shaker at 37 ℃ and 220rpm for 4.5 hours. Centrifugation was carried out at 10,000rpm for 10 minutes at 4 ℃ to discard the precipitate, 100. mu.l of the supernatant per well was used for ELISA detection, and the remaining supernatants were collected and stored at 4 ℃.
ELISA detection by dissolving the target FR α recombinant protein at a final concentration of 10. mu.g/ml in carbonate buffer [ pH9.6]In each well, 100. mu.l was coated overnight at 4 ℃ in a sealed wet box. Throwing out the redundant target molecule solution, beating and throwing away the redundant liquid on a clean paper towel, adding 200 mu l of sealing liquid into each hole, and sealing for 1-2 hours at 37 ℃. Throwing out the blocking liquid, washing for 6 times by TBST, beating and drying the enzyme label plate, sequentially adding 100 mu l of supernatant obtained from the deep-hole plate, reacting for 1-2 hours at room temperature, washing for 6 times by TBST (the same operation is carried out), diluting HRP-labeled anti-M13 antibody by the blocking liquid according to the proportion of 1: 10000, adding 100 mu l of blocking liquid into each hole, reacting for 1-2 hours at room temperature, fully washing for 6 times by TBST (the same step is carried out), adding 100 mu l of TMB substrate liquid (used in preparation) into each hole for color development, adding 50 mu l of 1M H into each hole after 10 minutes of light shielding effect, and then adding 50 mu l of TMB substrate liquid (used in preparation) into each hole2SO4Stopping the color reaction in a stopping solution, and detecting OD on a microplate reader450The value is obtained.
The results are shown in FIG. 2. Fig. 2A shows the preliminary detection results (the clone circled in fig. 2A is a folate receptor alpha specific binding peptide 4 display clone), and the clone is picked alone and verified to be capable of binding to the FR alpha recombinant protein through further ELISA experiments (fig. 2B), wherein PBS is used as a blank control, and the experimental group has a significant difference (P < 0.05) compared with the PBS control group.
(2) Preparation and sequencing identification of phage positive monoclonal DNA
According to the above ELISA results, a single positive phage clone was selected for amplification and then subjected to rapid purification of the sequencing module to generate a sufficiently pure template for sequencing: the overnight ER2738 culture was inoculated into LB medium at a ratio of 1: 100 and shaken to logarithmic phase, and then dispensed into 1ml culture tubes. Mu.l of phage positive clones were taken into the above 1ml culture tube. Shaking-culturing at 37 ℃ for 4.5-5 hours. The culture was transferred to a microcentrifuge tube and centrifuged for 30 seconds. The supernatant was transferred to a clean centrifuge tube, which was the amplified phage stock, and stored at 4 ℃ until the next experiment was not performed immediately.
And (3) rapid purification of a sequencing template: the phage-containing supernatant collected above (about 1ml in volume) was added with 400. mu.l of PEG/NaCl, mixed by inversion, left at room temperature for 10 minutes, centrifuged at 12,000rpm for 10 minutes, the supernatant was discarded, and centrifugation was carried out again, and the residual supernatant was thoroughly aspirated. The precipitate was added with 200. mu.l of iodide buffer (10mM Tris-HCl, 1mM EDTA, 4M NaI [ pH8.0]) and the precipitate was thoroughly resuspended, and then added with 500. mu.l of ethanol and incubated at room temperature for 10 minutes (to precipitate DNA); centrifuge at 12,000rpm for 10 minutes and discard the supernatant. Washing the precipitate with 1ml of pre-cooled 70% ethanol once, centrifuging at 12,000rpm for 10 min, removing the supernatant, opening the cover, and air drying overnight to fully volatilize ethanol. And finally, resuspending the precipitate in 30 mu l of double distilled water to obtain a sequencing template, detecting 5 mu l of the sequencing template by using 1% agarose gel electrophoresis, selecting-96 gIII sequencing primers from the DNA which is qualified by detection, sending the DNA to a company for sequencing, and analyzing the corresponding 12 peptide sequence of the phage.
By comparison, the applicant obtained a short peptide SEQ ID No. 1: YTNPYYSSHTRN are provided.
Example 4 cell ELISA for detecting binding of phage-displayed short peptides to cells
In order to verify the combination condition of the screened polypeptide and FR α expressed on the cell surface in a natural state, an ovarian cancer cell SKOV3 highly expressing FR α is selected, an irrelevant liver cancer cell HepG2 is set as a negative control, ELISA is carried out, the SKOV3 cell and the HepG2 cell are cultured until the cell density reaches more than 80%, the cell morphology is observed under a microscope to be good, the cell is digested by 0.25% of pancreatin, then corresponding fresh culture medium is added for basic suspension, viable cell counting is carried out, and the cell density is adjusted to 2 × 105Each well was plated with 96-well cell culture plates at 100. mu.l per well, and incubated overnight at 37 ℃. The supernatant was aspirated off every other day and sterile PBS buffer (137mM NaCl, 2.7mM KCl, 10mM Na)2HPO4,2mM KH2PO4[PH7.4]) Washing twice with 5 min each, fixing with 10% paraformaldehyde at room temperature for 15 min, removing the fixing solution, and washing the plate with 5% of PBS buffer solution 5 min each for 3 timesSkim milk (PBS diluted) was used as a blocking solution and blocked at 37 ℃ for 2 hours. The blocking solution was discarded, the PBS was briefly rinsed, the corresponding phage was diluted appropriately and added to the cell culture plate, and a set of negative controls (wild type M13) was set up, 100. mu.l per well, and incubated overnight at 4 ℃. The supernatant was aspirated off every other day and PBST (TBS + volume ratio 0.1% [ v/v ]]Tween-20) and PBS buffer were washed 3 times for 5 minutes each. Then, 100. mu.l of HRP-labeled anti-M13 antibody diluted with blocking solution to a working concentration (1: 10000) was added to each well, and incubated at 37 ℃ for 2 hours, followed by washing as above, and then the chromogenic reaction and the termination reaction were carried out in the same phage ELISA procedure.
The results are shown in FIG. 3. Compared with wild M13, the experimental group polypeptide has better binding with SKOV3, and has obvious specificity (P < 0.05) compared with the binding with HepG2, which indicates that the screened FR alpha binding peptide can be specifically bound with the FR alpha expressed on the surface of tumor cells in a natural state.
Example 5 detection of binding of phage-displayed short peptides to cell surface FR α by flow cytometry
Purpose of the experiment cocellular ELISA experiments were performed. And detecting the binding condition of the screened positive phage monoclonal to SKOV3 tumor cells by using flow cytometry.
Cell treatment, culturing SKOV3 cells until cell density reaches above 80%, observing cell morphology under microscope, digesting with 0.25% pancreatin, adding fresh culture medium to stop digestion, centrifuging at 1,500rpm for 5 min, re-suspending with PBS to prepare single cell suspension, counting living cells, and adjusting cell concentration to 1-2 × 106Each volume is divided into 1.5ml EP tubes, and each tube is 250-350 mul. And after centrifuging at 3,000rpm for 5 minutes, adding 100 mu l of diluted phage supernatant into each tube to serve as a primary antibody (the diluent is 2% FBS-PBS), selecting phage supernatant corresponding to the polypeptide obtained by sequencing, incubating for 1 hour at 4 ℃, taking out the phage supernatant at 3,000rpm, centrifuging for 5 minutes, discarding the supernatant, adding 1ml of PBS into each tube, washing for 2-3 times, and sucking and discarding the supernatant. Mu.l of diluted murine anti-M13 secondary antibody was added, left at 4 ℃ for 1 hour, removed and washed as above, and finally FITC-labeled goat anti-mouse fluorescent secondary antibody was added at a dilution ratio of 1: 500 (2% FBS-PBS) at 100. mu.l per well, taking care thatThis step requires the exclusion of light. Incubating at 4 ℃ in a dark place for 1 hour, washing the cells in the same way, adding a proper volume of PBS (phosphate buffer solution) for resuspension according to cell precipitation after the last washing, and detecting the cells by an up-flow cytometer.
From the binding results of flow cytometry, the phage supernatant was able to bind specifically to the cell line with high expression of FR α, as shown in fig. 4, the binding rate was 36%.
Claims (2)
1. A polypeptide targeting folate receptor alpha, characterized in that the amino acid sequence is SEQ ID No. 1:
Tyr-Thr-Asn-Pro-Tyr-Tyr-Ser-Ser-His-Thr-Arg-Asn。
2. a nucleic acid encoding the polypeptide of claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710649314.8A CN107793471B (en) | 2017-07-26 | 2017-07-26 | Folate receptor alpha specific binding peptide 4 and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710649314.8A CN107793471B (en) | 2017-07-26 | 2017-07-26 | Folate receptor alpha specific binding peptide 4 and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107793471A CN107793471A (en) | 2018-03-13 |
CN107793471B true CN107793471B (en) | 2020-08-11 |
Family
ID=61531509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710649314.8A Expired - Fee Related CN107793471B (en) | 2017-07-26 | 2017-07-26 | Folate receptor alpha specific binding peptide 4 and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107793471B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112021009912A2 (en) * | 2018-12-18 | 2022-01-18 | Navigo Proteins Gmbh | Folate receptor alpha binding protein, composition, and method for producing folr1 binding protein |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103432585A (en) * | 2013-07-30 | 2013-12-11 | 天津城建大学 | Targeted marking system for efficiently mediating folate receptor-alpha subtype |
CN103998605A (en) * | 2011-12-20 | 2014-08-20 | 诺维信股份有限公司 | Cellobiohydrolase variants and polynucleotides encoding same |
CN103998467A (en) * | 2011-07-15 | 2014-08-20 | 卫材R&D管理有限公司 | Anti-folate receptor alpha antibodies and uses thereof |
-
2017
- 2017-07-26 CN CN201710649314.8A patent/CN107793471B/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103998467A (en) * | 2011-07-15 | 2014-08-20 | 卫材R&D管理有限公司 | Anti-folate receptor alpha antibodies and uses thereof |
CN103998605A (en) * | 2011-12-20 | 2014-08-20 | 诺维信股份有限公司 | Cellobiohydrolase variants and polynucleotides encoding same |
CN103432585A (en) * | 2013-07-30 | 2013-12-11 | 天津城建大学 | Targeted marking system for efficiently mediating folate receptor-alpha subtype |
Non-Patent Citations (1)
Title |
---|
Primary structure of murine major histocompatibility complex alloantigens. Amino acid sequence of the NH2-terminal ninety-eight residues of the H-2Db glycoprotein.;W. Lee Maloy等;《J Biol Chem.》;19810525;第256卷(第6期);全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN107793471A (en) | 2018-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112010966B (en) | Monoclonal antibody aiming at non-RBD (radial basis function) region of new coronavirus spike protein and application thereof | |
WO2020043068A1 (en) | Ns1-binding protein and uses thereof | |
CN108017712B (en) | Protein skeleton derived from shark antibody and application thereof | |
Böttger et al. | Epitope mapping using phage display peptide libraries | |
KR20140080504A (en) | Screening methods and uses thereof | |
CN107793471B (en) | Folate receptor alpha specific binding peptide 4 and application thereof | |
CN107353325B (en) | Folate receptor alpha specific binding peptide 1 and application thereof | |
CN107446021B (en) | Folate receptor alpha specific binding peptide 5 and application thereof | |
EP4069371A1 (en) | Tools and methods to detect and isolate colibactin producing bacteria | |
WO2022262509A1 (en) | Leptin receptor affinity peptide and use thereof | |
Matz et al. | Phage display and selections on purified antigens | |
CN113121669B (en) | Antigen mimic epitope of human adiponectin and preparation method thereof | |
CN111393528B (en) | Single-chain antibody targeting folate receptor alpha and application thereof | |
JP4729043B2 (en) | Methods for screening antibody libraries | |
CN107446020B (en) | Folacin receptor alpha specific peptide 2 and its application | |
CN107674115A (en) | Folacin receptor alpha specific binding peptide 3 and its application | |
Colazet et al. | Phage display and selections on purified antigens | |
CN107513099A (en) | A kind of polystyrene affinity peptide and its method for improving antigen fixed effect | |
Jones et al. | Selection of antibodies to transiently expressed membrane proteins using phage display | |
CN110066337B (en) | anti-TNF-alpha antibody | |
CN106674334B (en) | Cry2 Ad-combined cyclic heptapeptide and encoding gene and application thereof | |
CN117964704A (en) | Peptide aptamer capable of specifically recognizing thyroxine as well as screening method and application thereof | |
Chen et al. | Isolation of human antibodies against hepatitis E virus from phage display library by immobilized metal affinity chromatography | |
Gunby | Phage-mediated Affinity Chromatography | |
CN117820432A (en) | Two polypeptide screening methods specifically combined with staphylococcus aureus and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200811 |